KR20140015127A - 폴리머 입자 및 이의 용도 - Google Patents

폴리머 입자 및 이의 용도 Download PDF

Info

Publication number
KR20140015127A
KR20140015127A KR1020127005296A KR20127005296A KR20140015127A KR 20140015127 A KR20140015127 A KR 20140015127A KR 1020127005296 A KR1020127005296 A KR 1020127005296A KR 20127005296 A KR20127005296 A KR 20127005296A KR 20140015127 A KR20140015127 A KR 20140015127A
Authority
KR
South Korea
Prior art keywords
antigen
particle
tuberculosis
subject
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127005296A
Other languages
English (en)
Korean (ko)
Inventor
베른드 헬무트 아담 렘
나탈리 앤 파레인
데이비드 닐 웨드록
브라이스 말콤 버들
Original Assignee
베른드 헬무트 아담 렘
브라이스 말콤 버들
데이비드 닐 웨드록
나탈리 앤 파레인
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베른드 헬무트 아담 렘, 브라이스 말콤 버들, 데이비드 닐 웨드록, 나탈리 앤 파레인 filed Critical 베른드 헬무트 아담 렘
Publication of KR20140015127A publication Critical patent/KR20140015127A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0208Specific bacteria not otherwise provided for
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/07Bacillus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/098Brucella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/14011Filoviridae
    • C12N2760/14111Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020127005296A 2009-07-29 2010-07-29 폴리머 입자 및 이의 용도 Ceased KR20140015127A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22934809P 2009-07-29 2009-07-29
US22931809P 2009-07-29 2009-07-29
US61/229,348 2009-07-29
US61/229,318 2009-07-29
PCT/IB2010/053465 WO2011013097A2 (en) 2009-07-29 2010-07-29 Polymer particles and uses thereof

Publications (1)

Publication Number Publication Date
KR20140015127A true KR20140015127A (ko) 2014-02-06

Family

ID=43529777

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127005296A Ceased KR20140015127A (ko) 2009-07-29 2010-07-29 폴리머 입자 및 이의 용도

Country Status (11)

Country Link
US (3) US20120201846A1 (https=)
EP (1) EP2461822A4 (https=)
JP (1) JP2013500329A (https=)
KR (1) KR20140015127A (https=)
CN (2) CN106421743A (https=)
AU (1) AU2010277222A1 (https=)
CA (1) CA2769645A1 (https=)
EA (1) EA201290072A1 (https=)
SG (1) SG178144A1 (https=)
WO (1) WO2011013097A2 (https=)
ZA (1) ZA201201482B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102180974B (zh) * 2011-03-22 2013-12-11 兰州大学 一种结核杆菌融合蛋白及其制备方法和应用
IN2014DN08675A (https=) * 2012-04-16 2015-05-22 Aeras Global Tb Vaccine Found
WO2013190453A2 (en) * 2012-06-18 2013-12-27 Tracy Thompson Compositions for separation methods
CN102716474B (zh) * 2012-06-27 2013-10-16 中国人民解放军军事医学科学院微生物流行病研究所 蛋白Rh054_01780在抗黑龙江立克次体的免疫保护中的应用
KR20150036593A (ko) * 2012-07-24 2015-04-07 사노피 파스퇴르 뎅기열 바이러스 감염 예방용 백신 조성물
US20140073022A1 (en) * 2012-09-10 2014-03-13 Wisconsin Alumni Research Foundation Production of polyhydroxyalkanoates with a defined composition from an unrelated carbon source
SMT202100585T1 (it) * 2014-02-04 2021-11-12 Polybatics Ltd Particelle di polimero e loro usi
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
GB2554206B (en) 2015-03-06 2021-03-24 Micromass Ltd Spectrometric analysis of microbes
WO2016142692A1 (en) 2015-03-06 2016-09-15 Micromass Uk Limited Spectrometric analysis
GB2552602B (en) * 2015-03-06 2020-12-30 Micromass Ltd Desorption electrospray ionisation mass spectrometry ("DESI-MS") analysis of swabs
US11139156B2 (en) 2015-03-06 2021-10-05 Micromass Uk Limited In vivo endoscopic tissue identification tool
CA2978042A1 (en) 2015-03-06 2016-09-15 Micromass Uk Limited Tissue analysis by mass spectrometry or ion mobility spectrometry
CN112964625B (zh) 2015-03-06 2024-06-07 英国质谱公司 细胞群体分析
EP3726562B1 (en) 2015-03-06 2023-12-20 Micromass UK Limited Ambient ionization mass spectrometry imaging platform for direct mapping from bulk tissue
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
EP3443354B1 (en) 2016-04-14 2025-08-20 Micromass UK Limited Spectrometric analysis of plants
BR112019004913B1 (pt) 2016-09-16 2022-07-12 Infectious Disease Research Institute Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
KR102107519B1 (ko) * 2018-06-25 2020-05-07 경상대학교산학협력단 브루셀라 어보투스 균주 유래의 InpB, Dps, AspC 및 Ndk 단백질을 유효성분으로 포함하는 브루셀라 감염증 예방 또는 치료용 백신 조성물
KR102317403B1 (ko) * 2019-01-28 2021-10-29 주식회사 바이오앱 당화된 Ag85A 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법
CN109813884A (zh) * 2019-03-25 2019-05-28 中国动物卫生与流行病学中心 一种牛结核病γ-干扰素快速检测制品
CN110411907B (zh) * 2019-06-19 2020-05-22 上海交通大学 植物叶片上亚微米颗粒物凝并效率测定方法、系统及介质
GB201913716D0 (en) * 2019-09-24 2019-11-06 Imp College Innovations Ltd Methods
JP7584763B2 (ja) * 2020-06-04 2024-11-18 東亞合成株式会社 抗ウイルス性ペプチドおよびその利用
CN117430664B (zh) * 2023-10-24 2024-04-09 暨南大学附属第六医院(东莞市东部中心医院) 一种甲型流感病毒t细胞抗原表位肽及其应用
CN118085043B (zh) * 2024-04-17 2024-07-19 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的多核苷酸、应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584866D1 (de) * 1984-09-12 1992-01-23 Chiron Corp Hybridpartikel-immunogene.
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
CA2285625C (en) * 1997-04-02 2015-06-30 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from m. tuberculosis
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU2003242504A1 (en) * 2002-07-13 2004-02-02 Statens Serum Institut Therapeutic tuberculosis vaccines
DE10240035A1 (de) * 2002-08-30 2004-03-11 Rehm, Bernd H.A., PD Dr.rer.nat. Biogene Polyester-Partikel definierter Größe mit funktionalisierten Oberflächen:Herstellungsverfahren und pharmazeutische Zubereitungen, in denen diese enthalten sind
EP1631264B8 (en) * 2003-06-02 2017-05-24 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
CA2612900C (en) * 2005-06-23 2016-08-09 Claus Aagaard Improved tuberculosis vaccines
EP1929010B1 (en) * 2005-09-27 2013-12-18 PolyBatics Limited Uses of polymer particles
CN100518821C (zh) * 2006-09-14 2009-07-29 复旦大学 Ag85B,ESAT-6的嵌合疫苗

Also Published As

Publication number Publication date
US20120201846A1 (en) 2012-08-09
CA2769645A1 (en) 2011-02-03
ZA201201482B (en) 2012-11-28
WO2011013097A3 (en) 2011-04-07
WO2011013097A2 (en) 2011-02-03
CN106421743A (zh) 2017-02-22
JP2013500329A (ja) 2013-01-07
CN102573891B (zh) 2016-06-01
EP2461822A2 (en) 2012-06-13
SG178144A1 (en) 2012-03-29
AU2010277222A1 (en) 2012-03-08
US20160175419A1 (en) 2016-06-23
CN102573891A (zh) 2012-07-11
US20180015156A1 (en) 2018-01-18
EA201290072A1 (ru) 2012-12-28
EP2461822A4 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
KR20140015127A (ko) 폴리머 입자 및 이의 용도
AU2019279084B2 (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
CN114058604B (zh) 一种融合蛋白及其在碱基编辑中的用途
KR102787119B1 (ko) 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
RU2761631C2 (ru) Белки rsv в предшествующей слиянию конформации и их применение
US20020188105A1 (en) Gain of function mutations in ATP-dependent transposition proteins
KR20170077238A (ko) Rna-유도 엔도뉴클레아제의 세포 내로의 펩티드 매개성 전달
KR102566066B1 (ko) 신규한 돼지 인플루엔자 백신
KR20120136349A (ko) 고가의 화학적 생성물의 미생물 생산, 및 관련 조성물, 방법 및 시스템
KR20140015136A (ko) 3-히드록시프로피온산 및 다른 생성물의 제조 방법
CN111465689B (zh) Cas9变体和使用方法
CN114222763A (zh) 在嵌合抗原受体设计中实现的超模块化IgG3间隔区结构域和多功能位点
MXPA03009632A (es) Proteinas de la envoltura de vhc glucosiladas en la estructura central.
CN111867637B (zh) 新ehv插入位点ul43
KR20230134524A (ko) 무장된 세네카 밸리 바이러스 종양용해 요법 조성물및 그의 방법
KR20230112625A (ko) 나이세리아 고노레아에 대한 백신접종을 위한 조성물 및 방법
BRPI0618672A2 (pt) bactérias e composições pró-apoptóticas para a distribuição e a expressão de antìgenos
CN112608932A (zh) 一种大肠杆菌中高效表达禽腺病毒Fiber-2蛋白的方法
CN100475964C (zh) Hcv复制子穿梭载体
US20230149526A1 (en) Combinations of flavivirus proteins, peptide sequences, epitopes, and methods and uses thereof
CN113025638B (zh) 一种基于双链核酸的折纸结构及其制备方法和应用
AU2023235203A1 (en) Therapeutic adeno-associated virus using codon optimized nucleic acid encoding alpha-glucosidase (gaa) for treating pompe disease, with signal peptide modifications
CN116322793A (zh) 改进的使用科卡尔包膜的t细胞转导用慢病毒载体的生成
US20210340183A1 (en) Artificial proteins and compositions and methods thereof
KR20150100606A (ko) 아테리바이러스 단백질 및 발현 메커니즘

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150724

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161118

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170418

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161118

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I